EXACTA · UNITED STATES
mTOR pathway combination study
Crook T and colleagues • Frontiers in Pharmacology • 2021
- DOI
- 10.3389/fphar.2021.631135
- Design
- Analysis of patients receiving profiling-informed combination regimens.
- Population
- 49 patients: 46 previously treated and 3 treatment-naïve.
- Endpoints
- Objective response, progression-free survival, and overall survival.
- Reported results
- Reported objective response was 57.1%; median progression-free survival was 4.9 months and overall survival 9.4 months.
- Limitations
- Small, heterogeneous cohort without a randomized comparator. It cannot isolate the contribution of profiling or establish superiority over standard care.
- Funding and conflicts
- Funded by Datar Cancer Genetics; author employment relationships are disclosed in the paper.